Reported relationships
Latest disclosed role at each company.
No relationships currently tracked through insider filings.
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
No balances currently tracked through insider filings.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Coherus Oncology, Inc.
Report date March 31, 2023 · Filed April 04, 2023
Section 16 reporting ended · disclosed 2023-04-04. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 116,361 |
Reported balance
After 2023-03-31 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2023-03-31 · Tax withholding · Disposed 16,278 · Balance 116,361 F1: Represents shares automatically withheld to pay related tax liability in connection with the vesting of restricted stock units in accordance with Rule 16b-3. F2: Includes 1,316 shares acquired on May 13, 2022, pursuant to the Coherus BioSciences, Inc. Employee Stock Purchase Plan. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares automatically withheld to pay related tax liability in connection with the vesting of restricted stock units in accordance with Rule 16b-3.
F2: Includes 1,316 shares acquired on May 13, 2022, pursuant to the Coherus BioSciences, Inc. Employee Stock Purchase Plan.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 31, 2023 Filed Apr 4, 2023 21:02 UTC | Coherus Oncology, Inc. CHRS · Entity 6276 | Tax withholdingCommon Stock | 16,278 | $6.84 | $111,341.52 |
DisclosureSEC source: 0001140361-23-016457 · form4.xml · nonDerivative · entry 1 Vexler Vladimir · CIK 0001759506 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 116,361 F1 · shares: Represents shares automatically withheld to pay related tax liability in connection with the vesting of restricted stock units in accordance with Rule 16b-3. F2 · balance_after: Includes 1,316 shares acquired on May 13, 2022, pursuant to the Coherus BioSciences, Inc. Employee Stock Purchase Plan. Read SEC document |
| January 20, 2023 Filed Jan 24, 2023 16:47 UTC | Coherus Oncology, Inc. CHRS · Entity 6276 | GrantCommon Stock | 40,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-23-001209 · doc1.xml · nonDerivative · entry 1 Vexler Vladimir · CIK 0001759506 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 131,323 F1 · shares: Constitute restricted stock units ("RSUs") for which the Reporting Person is entitled to receive one (1) share of Common Stock for each RSU upon vesting. 1/3 of the RSUs vest annually on January 20 of each year, with the first 1/3 vesting on January 20, 2024 and with the RSUs being fully vested on January 20, 2026, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date. Read SEC document |
| January 11, 2023 Filed Jan 12, 2023 16:37 UTC | Coherus Oncology, Inc. CHRS · Entity 6276 | Tax withholdingCommon Stock | 3,602 | $10.26 | $36,956.52 |
DisclosureSEC source: 0001567619-23-000892 · doc1.xml · nonDerivative · entry 2 Vexler Vladimir · CIK 0001759506 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 91,323 F1 · shares: Represents shares automatically withheld to pay related tax liability in connection with the vesting of restricted stock units in accordance with Rule 16b-3. Read SEC document |
| January 10, 2023 Filed Jan 12, 2023 16:37 UTC | Coherus Oncology, Inc. CHRS · Entity 6276 | Tax withholdingCommon Stock | 3,602 | $9.85 | $35,479.70 |
DisclosureSEC source: 0001567619-23-000892 · doc1.xml · nonDerivative · entry 1 Vexler Vladimir · CIK 0001759506 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 94,925 F1 · shares: Represents shares automatically withheld to pay related tax liability in connection with the vesting of restricted stock units in accordance with Rule 16b-3. Read SEC document |
| January 04, 2023 Filed Jan 6, 2023 18:15 UTC | Coherus Oncology, Inc. CHRS · Entity 6276 | GrantStock Option (Right to Buy) · Derivative | 80,000 | $0.00 Strike: $9.87 | $0.00 |
DisclosureSEC source: 0001567619-23-000696 · doc1.xml · derivative · entry 2 Vexler Vladimir · CIK 0001759506 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,000 Underlying: Common Stock · 80,000 shares Expires 2033-01-04 F3 · derivative.exercise_date: The underlying shares subject to the option vest and become exercisable as to 1/48th of the total number of shares subject to the option in successive, equal monthly installments measured from January 4, 2023, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date. Read SEC document |
| January 04, 2023 Filed Jan 6, 2023 18:15 UTC | Coherus Oncology, Inc. CHRS · Entity 6276 | Tax withholdingCommon Stock | 5,437 | $9.87 | $53,663.19 |
DisclosureSEC source: 0001567619-23-000696 · doc1.xml · nonDerivative · entry 1 Vexler Vladimir · CIK 0001759506 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 98,527 F1 · shares: Represents shares automatically withheld to pay related tax liability in connection with the vesting of restricted stock units in accordance with Rule 16b-3. F2 · balance_after: Includes 1 share acquired on November 15, 2022, pursuant to Coherus BioSciences, Inc. Employee Stock Purchase Plan. Read SEC document |
| April 01, 2022 Filed Apr 5, 2022 17:19 UTC | Coherus Oncology, Inc. CHRS · Entity 6276 | Tax withholdingCommon Stock | 3,458 | $12.85 | $44,435.30 |
DisclosureSEC source: 0001567619-22-008113 · doc1.xml · nonDerivative · entry 1 Vexler Vladimir · CIK 0001759506 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 103,963 F1 · kind: Represents shares automatically withheld to satisfy tax withholding obligations in connection with the vesting of restricted stock units ("RSUs"). F1 · shares: Represents shares automatically withheld to satisfy tax withholding obligations in connection with the vesting of restricted stock units ("RSUs"). Read SEC document |
| January 11, 2022 Filed Jan 12, 2022 16:39 UTC | Coherus Oncology, Inc. CHRS · Entity 6276 | Tax withholdingCommon Stock | 3,583 | $14.36 | $51,451.88 |
DisclosureSEC source: 0001567619-22-001114 · doc1.xml · nonDerivative · entry 2 Vexler Vladimir · CIK 0001759506 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 107,421 F3 · shares: Represents the number of shares of common stock withheld to pay the related tax liability on RSUs that vested on January 11, 2022. F4 · balance_after: Includes 91,249 RSUs. Read SEC document |
| January 10, 2022 Filed Jan 12, 2022 16:39 UTC | Coherus Oncology, Inc. CHRS · Entity 6276 | Tax withholdingCommon Stock | 4,150 | $14.30 | $59,345.00 |
DisclosureSEC source: 0001567619-22-001114 · doc1.xml · nonDerivative · entry 1 Vexler Vladimir · CIK 0001759506 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 111,004 F1 · shares: Represents the number of shares of common stock withheld to pay the related tax liability on restricted stock units ("RSUs") that vested on January 10, 2022. F2 · balance_after: Includes 101,666 RSUs. Read SEC document |
| January 04, 2022 Filed Jan 6, 2022 19:48 UTC | Coherus Oncology, Inc. CHRS · Entity 6276 | GrantStock Option (Right to Buy) · Derivative | 80,000 | $0.00 Strike: $15.94 | $0.00 |
DisclosureSEC source: 0001567619-22-000819 · doc1.xml · derivative · entry 2 Vexler Vladimir · CIK 0001759506 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,000 Underlying: Common Stock · 80,000 shares Expires 2032-01-04 F4 · derivative.exercise_date: The underlying shares subject to the option vest and become exercisable as to 1/48th of the total number of shares subject to the option in successive, equal monthly installments measured from January 4, 2022, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date. Read SEC document |
| January 04, 2022 Filed Jan 6, 2022 19:48 UTC | Coherus Oncology, Inc. CHRS · Entity 6276 | GrantCommon Stock | 40,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-22-000819 · doc1.xml · nonDerivative · entry 1 Vexler Vladimir · CIK 0001759506 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 115,154 F1 · shares: Constitute restricted stock units ("RSUs") for which the Reporting Person is entitled to receive one (1) share of Common Stock for each RSU upon vesting. 1/3 of the RSUs vest annually on January 4 of each year, with the first 1/3 vesting on January 4, 2023 and with the RSUs being fully vested on January 4, 2025, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date. F2 · balance_after: Includes 112,083 RSUs. F3 · balance_after: Includes 1,768 shares acquired on November 15, 2021, pursuant to Issuer's employee stock purchase plan. Read SEC document |
| April 28, 2021 Filed Apr 30, 2021 16:37 UTC | Coherus Oncology, Inc. CHRS · Entity 6276 | GrantCommon Stock | 20,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-21-008803 · doc1.xml · nonDerivative · entry 1 Vexler Vladimir · CIK 0001759506 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 73,386 F1 · shares: Constitute restricted stock units ("RSUs") for which the Reporting Person is entitled to receive one (1) share of Common Stock for each RSU upon vesting. 1/2 of the RSUs vest annually on April 1 of each year, with the first 1/2 vesting on April 1, 2022 and with the RSUs being fully vested on April 1, 2023, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date. F2 · balance_after: Includes 72,083 RSUs. Read SEC document |
| March 09, 2021 Filed Mar 11, 2021 17:37 UTC | Coherus Oncology, Inc. CHRS · Entity 6276 | Exercise / conversionStock Option (Right to Buy) · Derivative | 57,812 | $0.00 Strike: $10.05 | $0.00 |
DisclosureSEC source: 0001567619-21-006128 · doc1.xml · derivative · entry 7 Vexler Vladimir · CIK 0001759506 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,188 Underlying: Common Stock · 57,812 shares Expires 2028-02-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The underlying shares subject to the option vest and become exercisable as to 1/48th of the total number of shares subject to the option in successive, equal monthly installments measured from February 1, 2018, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date. Read SEC document |
| March 09, 2021 Filed Mar 11, 2021 17:37 UTC | Coherus Oncology, Inc. CHRS · Entity 6276 | Exercise / conversionStock Option (Right to Buy) · Derivative | 20,312 | $0.00 Strike: $9.30 | $0.00 |
DisclosureSEC source: 0001567619-21-006128 · doc1.xml · derivative · entry 6 Vexler Vladimir · CIK 0001759506 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,688 Underlying: Common Stock · 20,312 shares Expires 2027-11-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The underlying shares subject to the option vest and become exercisable as to 1/48th of the total number of shares subject to the option in successive, equal monthly installments measured from November 15, 2017, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date. Read SEC document |
| March 09, 2021 Filed Mar 11, 2021 17:37 UTC | Coherus Oncology, Inc. CHRS · Entity 6276 | Exercise / conversionStock Option (Right to Buy) · Derivative | 24,356 | $0.00 Strike: $2.08 | $0.00 |
DisclosureSEC source: 0001567619-21-006128 · doc1.xml · derivative · entry 5 Vexler Vladimir · CIK 0001759506 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 24,356 shares Expires 2023-02-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: All of the shares underlying this option are vested and exercisable as of the date hereof. Read SEC document |
| March 09, 2021 Filed Mar 11, 2021 17:37 UTC | Coherus Oncology, Inc. CHRS · Entity 6276 | SaleCommon Stock | 114,240 | $16.25 | $1,856,262.91 |
DisclosureSEC source: 0001567619-21-006128 · doc1.xml · nonDerivative · entry 4 Vexler Vladimir · CIK 0001759506 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,386 F2 · price: The transaction was executed in multiple trades at prices ranging from $16.071 to $16.50, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a stockholder of the Issuer, information regarding the number of shares and prices at which the transaction was effected. F1 · balance_after: Includes 52,083 restricted stock units. Read SEC document |
| March 09, 2021 Filed Mar 11, 2021 17:37 UTC | Coherus Oncology, Inc. CHRS · Entity 6276 | Exercise / conversionCommon Stock | 57,812 | $10.05 | $581,010.60 |
DisclosureSEC source: 0001567619-21-006128 · doc1.xml · nonDerivative · entry 3 Vexler Vladimir · CIK 0001759506 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 167,626 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 52,083 restricted stock units. Read SEC document |
| March 09, 2021 Filed Mar 11, 2021 17:37 UTC | Coherus Oncology, Inc. CHRS · Entity 6276 | Exercise / conversionCommon Stock | 20,312 | $9.30 | $188,901.60 |
DisclosureSEC source: 0001567619-21-006128 · doc1.xml · nonDerivative · entry 2 Vexler Vladimir · CIK 0001759506 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 109,814 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 52,083 restricted stock units. Read SEC document |
| March 09, 2021 Filed Mar 11, 2021 17:37 UTC | Coherus Oncology, Inc. CHRS · Entity 6276 | Exercise / conversionCommon Stock | 24,356 | $2.08 | $50,753.03 |
DisclosureSEC source: 0001567619-21-006128 · doc1.xml · nonDerivative · entry 1 Vexler Vladimir · CIK 0001759506 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 89,502 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 52,083 restricted stock units. Read SEC document |
| February 01, 2021 Filed Feb 3, 2021 17:39 UTC | Coherus Oncology, Inc. CHRS · Entity 6276 | GrantStock Option (Right to Buy) · Derivative | 50,000 | $0.00 Strike: $17.60 | $0.00 |
DisclosureSEC source: 0001567619-21-002144 · doc1.xml · derivative · entry 1 Vexler Vladimir · CIK 0001759506 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2031-02-01 F1 · derivative.exercise_date: On January 22, 2021, the compensation committee of the board of directors of Coherus BioSciences, Inc. approved the grant of an option to purchase 50,000 shares of common stock subject to the achievement of a certain performance milestone. 100% of the shares underlying this option were fully vested and exercisable at grant. Read SEC document |
| January 11, 2021 Filed Jan 13, 2021 16:24 UTC | Coherus Oncology, Inc. CHRS · Entity 6276 | GrantStock Option (Right to Buy) · Derivative | 62,500 | $0.00 Strike: $17.58 | $0.00 |
DisclosureSEC source: 0001567619-21-000983 · doc1.xml · derivative · entry 2 Vexler Vladimir · CIK 0001759506 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,500 Underlying: Common Stock · 62,500 shares Expires 2031-01-11 F3 · derivative.exercise_date: The underlying shares subject to the option vest and become exercisable as to 1/48th of the total number of shares subject to the option in successive, equal monthly installments measured from January 11, 2021, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date. Read SEC document |
| January 11, 2021 Filed Jan 13, 2021 16:24 UTC | Coherus Oncology, Inc. CHRS · Entity 6276 | GrantCommon Stock | 31,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-21-000983 · doc1.xml · nonDerivative · entry 1 Vexler Vladimir · CIK 0001759506 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,146 F1 · shares: Constitute restricted stock units ("RSUs") for which the Reporting Person is entitled to receive one (1) share of Common Stock for each RSU upon vesting. 1/3 of the RSUs vest annually on January 11 of each year, with the first 1/3 vesting on January 11, 2022 and with the RSUs being fully vested on January 11, 2024, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date. F2 · balance_after: Includes 52,083 RSUs. Read SEC document |
| January 10, 2021 Filed Jan 12, 2021 16:55 UTC | Coherus Oncology, Inc. CHRS · Entity 6276 | Tax withholdingCommon Stock | 4,080 | $18.18 | $74,174.40 |
DisclosureSEC source: 0001567619-21-000923 · doc1.xml · nonDerivative · entry 1 Vexler Vladimir · CIK 0001759506 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,896 F1 · balance_after: Includes 20,833 restricted stock units. F2 · balance_after: Includes 1,303 shares acquired on May 15, 2020, pursuant to Issuer's employee stock purchase plan. Read SEC document |
| December 10, 2020 Filed Dec 11, 2020 16:39 UTC | Coherus Oncology, Inc. CHRS · Entity 6276 | Exercise / conversionStock Option (Right to Buy) · Derivative | 17,626 | $0.00 Strike: $2.08 | $0.00 |
DisclosureSEC source: 0001567619-20-020979 · doc1.xml · derivative · entry 6 Vexler Vladimir · CIK 0001759506 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,356 Underlying: Common Stock · 17,626 shares Expires 2023-02-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: All of the shares underlying this option are vested and exercisable as of the date hereof. Read SEC document |
| December 10, 2020 Filed Dec 11, 2020 16:39 UTC | Coherus Oncology, Inc. CHRS · Entity 6276 | SaleCommon Stock | 17,626 | $18.05 | $318,066.46 |
DisclosureSEC source: 0001567619-20-020979 · doc1.xml · nonDerivative · entry 4 Vexler Vladimir · CIK 0001759506 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,673 F3 · price: The transaction was executed in multiple trades at prices ranging from $18.00 to $18.13, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a stockholder of the Issuer, information regarding the number of shares and prices at which the transaction was effected. F1 · balance_after: Includes 31,250 restricted stock units. Read SEC document |
| December 10, 2020 Filed Dec 11, 2020 16:39 UTC | Coherus Oncology, Inc. CHRS · Entity 6276 | Exercise / conversionCommon Stock | 17,626 | $2.08 | $36,729.06 |
DisclosureSEC source: 0001567619-20-020979 · doc1.xml · nonDerivative · entry 3 Vexler Vladimir · CIK 0001759506 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,299 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 31,250 restricted stock units. Read SEC document |
| December 09, 2020 Filed Dec 11, 2020 16:39 UTC | Coherus Oncology, Inc. CHRS · Entity 6276 | Exercise / conversionStock Option (Right to Buy) · Derivative | 30,000 | $0.00 Strike: $2.08 | $0.00 |
DisclosureSEC source: 0001567619-20-020979 · doc1.xml · derivative · entry 5 Vexler Vladimir · CIK 0001759506 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,982 Underlying: Common Stock · 30,000 shares Expires 2023-02-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: All of the shares underlying this option are vested and exercisable as of the date hereof. Read SEC document |
| December 09, 2020 Filed Dec 11, 2020 16:39 UTC | Coherus Oncology, Inc. CHRS · Entity 6276 | SaleCommon Stock | 49,512 | $18.24 | $903,084.03 |
DisclosureSEC source: 0001567619-20-020979 · doc1.xml · nonDerivative · entry 2 Vexler Vladimir · CIK 0001759506 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,673 F2 · price: The transaction was executed in multiple trades at prices ranging from $18.00 to $18.61, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a stockholder of the Issuer, information regarding the number of shares and prices at which the transaction was effected. F1 · balance_after: Includes 31,250 restricted stock units. Read SEC document |
| December 09, 2020 Filed Dec 11, 2020 16:39 UTC | Coherus Oncology, Inc. CHRS · Entity 6276 | Exercise / conversionCommon Stock | 30,000 | $2.08 | $62,514.00 |
DisclosureSEC source: 0001567619-20-020979 · doc1.xml · nonDerivative · entry 1 Vexler Vladimir · CIK 0001759506 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 86,185 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 31,250 restricted stock units. Read SEC document |
| January 10, 2020 Filed Jan 14, 2020 17:49 UTC | Coherus Oncology, Inc. CHRS · Entity 6276 | GrantStock Option (Right to Buy) · Derivative | 62,500 | $0.00 Strike: $17.73 | $0.00 |
DisclosureSEC source: 0001567619-20-001040 · doc1.xml · derivative · entry 4 Vexler Vladimir · CIK 0001759506 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,500 Underlying: Common Stock · 62,500 shares Expires 2030-01-10 F4 · derivative.exercise_date: The underlying shares subject to the option vest and become exercisable as to 1/48th of the total number of shares subject to the option in successive, equal monthly installments measured from January 10, 2020, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date. Read SEC document |
| January 10, 2020 Filed Jan 14, 2020 17:49 UTC | Coherus Oncology, Inc. CHRS · Entity 6276 | GrantCommon Stock, $0.0001 par value | 31,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-20-001040 · doc1.xml · nonDerivative · entry 3 Vexler Vladimir · CIK 0001759506 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,185 F2 · shares: Constitute restricted stock units ("RSUs") for which the Reporting Person is entitled to receive one (1) share of Common Stock for each RSU upon vesting. 1/3 of the RSUs vest annually on January 10 of each year, with the first 1/3 vesting on January 10, 2021 and with the RSUs being fully vested on January 10, 2023, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date. F1 · balance_after: Includes 2,038 shares acquired on May 15, 2019, pursuant to Issuer's employee stock purchase plan. F3 · balance_after: Includes 31,250 RSUs. Read SEC document |
| January 10, 2020 Filed Jan 14, 2020 17:49 UTC | Coherus Oncology, Inc. CHRS · Entity 6276 | Tax withholdingCommon Stock, $0.0001 par value | 3,477 | $17.73 | $61,647.21 |
DisclosureSEC source: 0001567619-20-001040 · doc1.xml · nonDerivative · entry 2 Vexler Vladimir · CIK 0001759506 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,935 F1 · balance_after: Includes 2,038 shares acquired on May 15, 2019, pursuant to Issuer's employee stock purchase plan. Read SEC document |
| January 10, 2020 Filed Jan 14, 2020 17:49 UTC | Coherus Oncology, Inc. CHRS · Entity 6276 | GrantCommon Stock, $0.0001 par value | 8,900 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-20-001040 · doc1.xml · nonDerivative · entry 1 Vexler Vladimir · CIK 0001759506 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,412 F1 · balance_after: Includes 2,038 shares acquired on May 15, 2019, pursuant to Issuer's employee stock purchase plan. Read SEC document |
| January 11, 2019 Filed Jan 15, 2019 16:05 UTC | Coherus Oncology, Inc. CHRS · Entity 6276 | GrantStock Option (Right to Buy) · Derivative | 126,000 | $0.00 Strike: $12.37 | $0.00 |
DisclosureSEC source: 0000899243-19-001200 · doc4.xml · derivative · entry 3 Vexler Vladimir · CIK 0001759506 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 126,000 Underlying: Common Stock · 126,000 shares Expires 2029-01-11 F1 · derivative.exercise_date: The underlying shares subject to the option vest and become exercisable as to 1/48th of the total number of shares subject to the option in successive, equal monthly installments measured from January 11, 2019, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date. Read SEC document |
| January 11, 2019 Filed Jan 15, 2019 16:05 UTC | Coherus Oncology, Inc. CHRS · Entity 6276 | Tax withholdingCommon Stock, $0.0001 par value | 5,916 | $12.37 | $73,180.92 |
DisclosureSEC source: 0000899243-19-001200 · doc4.xml · nonDerivative · entry 2 Vexler Vladimir · CIK 0001759506 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,474 Read SEC document |
| January 11, 2019 Filed Jan 15, 2019 16:05 UTC | Coherus Oncology, Inc. CHRS · Entity 6276 | GrantCommon Stock, $0.0001 par value | 15,562 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-19-001200 · doc4.xml · nonDerivative · entry 1 Vexler Vladimir · CIK 0001759506 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,390 Read SEC document |
| November 16, 2018 Filed Nov 20, 2018 16:12 UTC | Coherus Oncology, Inc. CHRS · Entity 6276 | GrantStock Option (Right to Buy) · Derivative | 35,000 | $0.00 Strike: $12.27 | $0.00 |
DisclosureSEC source: 0000899243-18-029452 · doc4.xml · derivative · entry 2 Vexler Vladimir · CIK 0001759506 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,000 Underlying: Common Stock · 35,000 shares Expires 2028-11-16 F1 · derivative.exercise_date: The underlying shares subject to the option vest and become exercisable as to 1/48th of the total number of shares subject to the option in successive, equal monthly installments measured from November 16, 2018, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date. Read SEC document |
| November 16, 2018 Filed Jan 14, 2019 16:08 UTC Amendment | Coherus Oncology, Inc. CHRS · Entity 6276 | GrantStock Option (Right to Buy) · Derivative | 35,000 | $0.00 Strike: $12.27 | $0.00 |
DisclosureSEC source: 0000899243-19-001121 · doc4a.xml · derivative · entry 2 Vexler Vladimir · CIK 0001759506 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,000 Underlying: Common Stock · 35,000 shares Expires 2028-11-16 F2 · derivative.exercise_date: The underlying shares subject to the option vest and become exercisable as to 1/48th of the total number of shares subject to the option in successive, equal monthly installments measured from November 16, 2018, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date. Read SEC document |
| November 16, 2018 Filed Jan 15, 2019 10:05 UTC Amendment | Coherus Oncology, Inc. CHRS · Entity 6276 | GrantStock Option (Right to Buy) · Derivative | 35,000 | $0.00 Strike: $12.27 | $0.00 |
DisclosureSEC source: 0000899243-19-001180 · doc4a.xml · derivative · entry 2 Vexler Vladimir · CIK 0001759506 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,000 Underlying: Common Stock · 35,000 shares Expires 2028-11-16 F2 · derivative.exercise_date: The underlying shares subject to the option vest and become exercisable as to 1/48th of the total number of shares subject to the option in successive, equal monthly installments measured from November 16, 2018, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.